BioPharma Drive: Drug Pricing

MAY 27, 2025

Elsewhere, Angelini Pharma licensed a rare disease therapy and the FDA refused to review a Savara lung drug. City will receive $46 million from Biogen under the alliance.

Licensing 191

Licensing Licensing FDA Therapies 191

BioPharma Drive: Drug Pricing

NOVEMBER 19, 2024

Elsewhere, former NCI director Ned Sharpless founded a new startup and Novartis licensed another radiopharma drug. The agency turned back Astellas’ attempt to update its drug Izervay’s labeling.

Licensing 147

Licensing Licensing FDA Drugs 147

BioPharma Drive: Drug Pricing

MAY 21, 2025

Founded in 2021, ReproNovo has licensed rights to two drugs from Mereo BioPharma and ObsEva that it thinks could address fertility issues in men and women.

Licensing 147

Licensing Licensing Drugs 147

BioPharma Drive: Drug Pricing

NOVEMBER 13, 2023

With the deal, the Swiss pharma is exploring a tumor target, DLL3, that’s thwarted past drugmaker efforts to attack it.

Licensing 200

Licensing Licensing Therapies 200

Drug Patent Watch

JULY 30, 2024

The Power of Patent Licensing: Unlocking Innovation and Access to Medicines Patent licensing agreements have become a crucial tool in the pharmaceutical industry, allowing companies to collaborate and…

Licensing 101

Licensing Licensing Pharmaceuticals Drugs 101

BioPharma Drive: Drug Pricing

APRIL 7, 2025

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across the blood-brain barrier.

Licensing 173

Licensing Licensing Disease Drugs 173

BioPharma Drive: Drug Pricing

OCTOBER 22, 2024

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for its clinical-stage treatment reni-cel.

Therapies 299

Therapies Licensing Licensing Treatment 299

BioPharma Drive: Drug Pricing

JULY 3, 2024

The mRNA specialist plans to eliminate 30% of its workforce as part of a restructuring that will prioritize “high-value” projects like its cancer vaccines.

Vaccine 182

Vaccine Licensing Licensing 182

BioPharma Drive: Drug Pricing

DECEMBER 2, 2024

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly 250-person study that should produce results next year.

Licensing 290

Licensing Licensing Drugs 290

Drug Discovery Today

DECEMBER 2, 2020

Sanyou signs two commercial-use licenses for Horizon’s gene-edited CHO-K1 GS knockout cell line, for use in biotherapeutic pipeline development and contract research services

Licensing 113

Licensing Licensing Research 113

BioPharma Drive: Drug Pricing

DECEMBER 12, 2023

Just before clearing Pfizer’s buyout of Seagen, the regulator threatened to block Sanofi’s licensing deal with Maze Therapeutics, a challenge the biotech called ‘‘unprecedented.”

Drug Research 309

Drug Research Licensing Licensing Research 309

Drug Patent Watch

MAY 13, 2025

"Unlocking the Secrets to Smarter Partnerships: How One Tool is Revolutionizing the Way Pharma Companies Approach Out-Licensing and Partnering Decisions As the pharmaceutical industry continues to evolve, companies are under increasing pressure to maximize their portfolios and minimize risk.

Licensing 91

Licensing Licensing Pharma Companies Pharmaceuticals 91

BioPharma Drive: Drug Pricing

MARCH 28, 2024

Xilio will get just over $40 million from Gilead in return for a license to its experimental IL-12 immunotherapy. The biotech is also discontinuing other work and laying off staff.

Licensing 298

Licensing Licensing Drugs 298

BioPharma Drive: Drug Pricing

FEBRUARY 8, 2024

The German biotech will invest $200 million in Autolus — funds that, along with a $50 million fee, will give it licensing opportunities and access to supply infrastructure.

Therapies 292

Therapies Licensing Licensing 292

BioPharma Drive: Drug Pricing

APRIL 17, 2025

The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at multiple popular immune disease targets, such as TL1A and IL23.

Licensing 147

Licensing Licensing Disease Drugs 147

BioPharma Drive: Drug Pricing

JANUARY 14, 2025

Nippon Shinyaku will pay Regenxbio $110 million upfront for U.S. and Asia rights to treatments for Hunter and Hurler syndromes.

Licensing 147

Licensing Licensing Therapies Treatment 147

BioPharma Drive: Drug Pricing

OCTOBER 18, 2024

European regulators have for the fourth time issued a negative opinion on PTC's Translarna. Elsewhere, Amylyx read out data and Leqembi hit a roadblock in Australia.

Licensing 173

Licensing Licensing Regulations Drugs 173

BioPharma Drive: Drug Pricing

JANUARY 9, 2025

The newly launched biotech is equipped with rights to a trio of weight loss medicines licensed from China-based Sciwind Biosciences, led by an oral therapy ready for Phase 2 testing.

Licensing 263

Licensing Licensing Therapies Drugs 263

Science Daily: Pharmacology News

MAY 28, 2025

Neurons deep in the brain not only help to initiate movement -- they also actively suppress it, and with astonishing precision. The findings are especially relevant for better understanding neurological disorders such as Parkinson's disease.

Licensing 152

Licensing Licensing Disease 152

BioPharma Drive: Drug Pricing

MARCH 3, 2025

Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer Hummingbird Bioscience.

Licensing 254

Licensing Licensing Drug Development Drugs 254

BioPharma Drive: Drug Pricing

OCTOBER 2, 2024

The company will permit six generic drugmakers to make and sell lenacapavir in 120 countries that have high incidence of the disease but limited resources.

Licensing 162

Licensing Licensing Disease Drugs 162

BioPharma Drive: Drug Pricing

MARCH 12, 2025

Ionis’ drug, sapablursen, is currently being tested in a Phase 2 trial in patients with polycythemia vera.

Licensing 147

Licensing Licensing Disease Drugs 147

BioPharma Drive: Drug Pricing

MARCH 13, 2025

The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic focus, executives said on a conference call.

Licensing 246

Licensing Licensing Drugs 246

BioPharma Drive: Drug Pricing

JUNE 1, 2025

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a bispecific antibody newly licensed by Pfizer.

Licensing 162

Licensing Licensing Doctors 162

BioPharma Drive: Drug Pricing

JULY 10, 2023

The pharma company will pay $30 million upfront to gain rights to an experimental therapy meant to enhance the anti-tumor effect of radiation.

Licensing 147

Licensing Licensing Pharma Companies Treatment 147

BioPharma Drive: Drug Pricing

JULY 9, 2025

Published July 9, 2025 Gwendolyn Wu Senior reporter post share post print email license Actinium is one of several radioisotopes favored by biotechnology companies developing drugs for cancer.

Drugs 133

Drugs Clinical Development Therapies Clinical Trials 133

BioPharma Drive: Drug Pricing

MARCH 25, 2025

A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a genetic risk factor called lipoprotein(a).

Licensing 225

Licensing Licensing Pharmaceuticals 225

BioPharma Drive: Drug Pricing

JUNE 8, 2023

Two-year-old Kate Therapeutics is launching publicly with $51 million in funding and a licensing deal with Astellas Pharma for a neuromuscular disease gene therapy.

Therapies 246

Therapies Disease Licensing Licensing 246

Drug Patent Watch

DECEMBER 10, 2024

“Patent thickets can lead to holdup of innovations, increases in the complexity of negotiations over licenses and increases in litigation, and can also create incentives to add more and weaker patents to the patent system. Cross-licensing agreements: To navigate patent thickets, many companies enter into cross-licensing agreements.

Licensing 98

Licensing Licensing International Marketing 98

BioPharma Drive: Drug Pricing

DECEMBER 4, 2024

Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program and Takeda acquired a blood disease therapy.

Licensing 147

Licensing Licensing Drugs Therapies 147

BioPharma Drive: Drug Pricing

JULY 10, 2023

The licensing agreement for the biotech’s viral vector platform follows recent Astellas agreements with Taysha Gene Therapies and Kate Therapeutics.

Therapies 229

Therapies Licensing Licensing 229

BioPharma Drive: Drug Pricing

MARCH 3, 2025

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with drugs from Novo Nordisk, Eli Lilly and Zealand.

Licensing 205

Licensing Licensing Therapies Drugs 205

BioPharma Drive: Drug Pricing

AUGUST 1, 2023

Some on Wall Street believe the New York-based biotechnology company is now less likely to get acquired after agreeing to sell partial rights to its only marketed product.

Licensing 130

Licensing Licensing Production Marketing 130

Drug Discovery Today

APRIL 22, 2020

Cambridge, UK, and Brisbane, CA, 21 April 2020 Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo) (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a collaboration and exclusive license (..)

Licensing 100

Licensing Licensing Engineering Therapies 100

BioPharma Drive: Drug Pricing

MARCH 24, 2025

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.

Licensing 189

Licensing Licensing Drugs 189

Drug Discovery Today

JANUARY 26, 2022

a leading provider of integrated drug discovery services to life science organisations globally, is delighted that Professors Daniel Longley, Tim Harrison and colleagues at Queen’s University Belfast have entered into a collaboration and licensing agreement with Ipsen. Saffron Walden, 26th January 2022 / Domainex Ltd.,

Licensing 100

Licensing Licensing Science Research 100

Drug Discovery Today

JULY 7, 2022

Pfizer and Touchlight agree to patent license for Pfizer to utilise rapid, scalable, enzymatic doggybone DNA (dbDNA) in Pfizer’s clinical and commercial manufacture of its mRNA vaccines, therapeutics, and gene therapiesAgreement includes upfront payment, potential development and commercial milestone payments, and royalties upon commercializationAccess (..)

Licensing 100

Licensing Licensing Vaccine DNA 100